Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Tumor suppressive functions of p53.

Zilfou JT, Lowe SW.

Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a001883. doi: 10.1101/cshperspect.a001883. Review.

2.

ARF induces autophagy by virtue of interaction with Bcl-xl.

Pimkina J, Humbey O, Zilfou JT, Jarnik M, Murphy ME.

J Biol Chem. 2009 Jan 30;284(5):2803-10. doi: 10.1074/jbc.M804705200. Epub 2008 Dec 2.

3.

The ARF tumor suppressor can promote the progression of some tumors.

Humbey O, Pimkina J, Zilfou JT, Jarnik M, Dominguez-Brauer C, Burgess DJ, Eischen CM, Murphy ME.

Cancer Res. 2008 Dec 1;68(23):9608-13. doi: 10.1158/0008-5472.CAN-08-2263.

4.

The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway.

Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, Watnick T, Henske EP.

Hum Mol Genet. 2009 Jan 1;18(1):151-63. doi: 10.1093/hmg/ddn325. Epub 2008 Oct 9.

5.

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.

Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES.

J Clin Invest. 2007 Jan;117(1):218-28. Epub 2006 Dec 7.

6.

Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines.

Reed MF, Zagorski WA, Howington JA, Zilfou JT, Knudsen ES.

Ann Thorac Surg. 2006 Jul;82(1):249-53.

PMID:
16798224
7.

Slugging it out: fine tuning the p53-PUMA death connection.

Zilfou JT, Spector MS, Lowe SW.

Cell. 2005 Nov 18;123(4):545-8.

8.

Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.

Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW.

Nat Genet. 2005 Nov;37(11):1289-95. Epub 2005 Oct 2. Erratum in: Nat Genet. 2006 Mar;38(3):389.

PMID:
16200064
9.

Suppression of tumorigenesis by the p53 target PUMA.

Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ, Lowe SW.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9333-8. Epub 2004 Jun 10.

10.

An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.

Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, Lowe SW.

Nat Genet. 2003 Mar;33(3):396-400. Epub 2003 Feb 3.

PMID:
12567186
11.

Transcriptional repression of the anti-apoptotic survivin gene by wild type p53.

Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M.

J Biol Chem. 2002 Feb 1;277(5):3247-57. Epub 2001 Nov 19.

12.

Indoloquinoxaline compounds that selectively antagonize P-glycoprotein.

Smith CD, Myers CB, Zilfou JT, Smith SN, Lawrence DS.

Oncol Res. 2000;12(5):219-29.

PMID:
11417747
13.

The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.

Zilfou JT, Hoffman WH, Sank M, George DL, Murphy M.

Mol Cell Biol. 2001 Jun;21(12):3974-85.

14.

Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs.

Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD.

J Pharmacol Exp Ther. 2001 Jun;297(3):1067-73.

PMID:
11356930
15.

Structure-activity studies of cerulenin analogues as protein palmitoylation inhibitors.

Lawrence DS, Zilfou JT, Smith CD.

J Med Chem. 1999 Dec 2;42(24):4932-41.

PMID:
10585203
17.

Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins.

Smith CD, Zilfou JT, Zhang X, Hudes GR, Tew KD.

Cancer. 1995 May 15;75(10):2597-604.

PMID:
7736407
18.

Welwitindolinone analogues that reverse P-glycoprotein-mediated multiple drug resistance.

Smith CD, Zilfou JT, Stratmann K, Patterson GM, Moore RE.

Mol Pharmacol. 1995 Feb;47(2):241-7.

PMID:
7870031
19.

Differential interactions of cytochalasins with P-glycoprotein.

Zilfou JT, Smith CD.

Oncol Res. 1995;7(9):435-43.

PMID:
8835287

Supplemental Content

Loading ...
Support Center